Background: Cardiovascular diseases continue to be the top cause of death disability worldwide. One emerging concern during (CAG) percutaneous interventions (PCI) is contrast-induced nephropathy (CIN), which is especially dangerous for diabetic patients. This study's overarching goal is to determine whether diabetic patients who suffer from -ST segment elevation myocardial infarction (NSTEMI) are more likely to develop CIN when treated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. Methods: The Shebin Elkom Teaching Hospital served as the site of a prospective, single-center study that ran from August 1, 2023, to August 1, 2024. The research comprised 300 individuals with 2 mellitus, ranging in age from 24 to 80 years, split evenly between two groups: one group that used SGLT2 inhibitors (case group) another group that did not (control group). The of CIN was based on previously established criteria, serum creatinine levels were recorded both before after the procedure. Conclusions: The case group had a significantly lower incidence of CIN (5.33%) the control group (20.67%, P<0.001). Three days (P=0.035) seven days (P=0.001) after the operation, the case group's serum creatinine levels were noticeably lower. A decrease in CIN incidence was found to be significantly predicted by using SGLT2 inhibitors in both univariate multivariate analyses. Conclusion: SGLT2 inhibitor-using diabetic patients are much less likely to experience CIN during CAG PCI -users.